Innate Pharma (IPHA) Asset Writedowns and Impairment (2020 - 2022)
Innate Pharma (IPHA) reported Asset Writedowns and Impairment of -$41830.1 for Q4 2022, up 99.92% quarter-over-quarter from -$51.9 million in Q4 2020.
Innate Pharma (IPHA) Asset Writedowns and Impairment (2020 - 2022) Analysis & Trends
Innate Pharma has reported Asset Writedowns and Impairment for 2 years, with the latest figure at -$41830.1 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Innate Pharma | 194.19 Mn | 194.19 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | -41,830.14 |
| Dec 31, 2022 | -41,830.14 |
| Dec 31, 2020 | -51.90 Mn |
| Dec 31, 2020 | -51.90 Mn |